The company's real-time image-guided device uses ultrasounds to treat calcified aortic stenosis with no thermal injury, resulting in a higher likelihood of successful treatment. Cardiawave has secured over €14m since inception and has won multiple innovation prizes. The device uses focused ultrasound therapy to soften aortic valve leaflets and improve valve opening, addressing a major public health concern in Western countries affecting 10 million people. First-in-man is expected in 2019.